Cargando…

Patient Perspectives on Anti-spike Monoclonal Antibody Therapy for Mild to Moderate Coronavirus Disease-2019

Anti-spike monoclonal antibodies emerged as effective early treatment of high-risk individuals with mild-to-moderate COVID-19. Although their clinical and safety outcomes have been reported, patient perspectives of these experimental therapies have not been evaluated. In this survey participated by...

Descripción completa

Detalles Bibliográficos
Autores principales:	Razonable, Raymund R, Ganesh, Ravindra, Bishop, Rachel K, Culbertson, Tracy L, Destro Borgen, Molly, Hedin, Michelle C, Hopkins, Laura H, Jackson, Tammy A, Larsen, Jennifer J, Matoush, Jennifer A, Moehnke, Darcie E, Olson, Shelly M, Peterson, Kellie M, Rosedahl, Jordan, Philpot, Lindsey M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234828/ https://www.ncbi.nlm.nih.gov/pubmed/35769314 http://dx.doi.org/10.1177/23743735221105673

Ejemplares similares

Influence of Social and Cultural Factors on the Decision to Consent for Monoclonal Antibody Treatment among High-Risk Patients with Mild-Moderate COVID-19
por: Bierle, Dennis M., et al.
Publicado: (2021)

519. Early Transition to Outpatient Remdesivir Increases Patient Satisfaction while Decreasing Hospital Costs
por: Chesdachai, Supavit, et al.
Publicado: (2023)

Clinical Prioritization of Antispike Monoclonal Antibody Treatment of Mild to Moderate COVID-19
por: Razonable, Raymund R., et al.
Publicado: (2022)

Breakthrough COVID-19 and casirivimab-imdevimab treatment during a SARS-CoV-2 B1.617.2 (Delta) surge
por: Bierle, Dennis M., et al.
Publicado: (2021)

Casirivimab–Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19
por: Razonable, Raymund R., et al.
Publicado: (2021)

A Framework for Outpatient Infusion of Antispike Monoclonal Antibodies to High-Risk Patients with Mild-to-Moderate Coronavirus Disease-19: The Mayo Clinic Model
por: Razonable, Raymund R., et al.
Publicado: (2021)

Managing Patients in the COVID-19 Pandemic: A Virtual Multidisciplinary Approach
por: Ganesh, Ravindra, et al.
Publicado: (2020)

Curbing the Delta Surge: Clinical Outcomes After Treatment With Bamlanivimab-Etesevimab, Casirivimab-Imdevimab, or Sotrovimab for Mild to Moderate Coronavirus Disease 2019
por: Razonable, Raymund R., et al.
Publicado: (2022)

Monoclonal Antibody Therapy for COVID-19 in Solid Organ Transplant Recipients
por: Yetmar, Zachary A, et al.
Publicado: (2021)

Outcomes of B-Cell-Depleted Patients With Coronavirus Disease 2019 Treated With Antispike Monoclonal Antibodies
por: Yetmar, Zachary A, et al.
Publicado: (2022)

Real-world Clinical Outcomes of Bebtelovimab and Sotrovimab Treatment of High-risk Persons With Coronavirus Disease 2019 During the Omicron Epoch
por: Razonable, Raymund R, et al.
Publicado: (2022)

518. Comparable Outcomes of Remdesivir and Sotrovimab among High-risk Patients with Mild to Moderate COVID-19 During the Omicron BA.1 Surge
por: Chesdachai, Supavit, et al.
Publicado: (2023)

COVID-19 and Solid Organ Transplantation: Role of Anti-SARS-CoV-2 Monoclonal Antibodies
por: Dhand, Abhay, et al.
Publicado: (2022)

Anti-Spike Monoclonal Antibody Therapy in Pregnant Women With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)
por: Thilagar, Bright P., et al.
Publicado: (2022)

Changes in substance use among young adults during a respiratory disease pandemic
por: Sharma, Pravesh, et al.
Publicado: (2020)

Integrating Infectious Diseases and Preventive Medicine Specialties Into 1 Division: Experience of an Academic Medical Center
por: Murad, M. Hassan, et al.
Publicado: (2023)

Antiviral Drugs for Viruses Other Than Human Immunodeficiency Virus
por: Razonable, Raymund R.
Publicado: (2011)

Loneliness and Migraine Self-Management: A Cross-Sectional Assessment
por: Lui, Jacob Z., et al.
Publicado: (2020)

Cytomegalovirus Infections in Solid Organ Transplantation: A Review
por: Ramanan, Poornima, et al.
Publicado: (2013)

1565. Lymphocyte Subsets as Predictors of Cytomegalovirus Infection After Transplantation
por: Meesing, Atibordee, et al.
Publicado: (2018)

Absolute Lymphocyte Count Thresholds: A Simple, Readily Available Tool to Predict the Risk of Cytomegalovirus Infection After Transplantation
por: Meesing, Atibordee, et al.
Publicado: (2018)

Editorial: Neutralizing Antibodies in the Prevention and Treatment of COVID-19
por: Razonable, Raymund R., et al.
Publicado: (2022)

Central Sensitization Symptom Severity and Patient-Provider Relationships in a Community Setting
por: Wang, Xiao Jing, et al.
Publicado: (2021)

Letermovir and inhibitors of the terminase complex: a promising new class of investigational antiviral drugs against human cytomegalovirus
por: Melendez, Dante P, et al.
Publicado: (2015)

604 Risk Factors for Cytomegalovirus (CMV) Reactivation in CMV-seropositive Liver Transplant Patients
por: Bruminhent, Jackrapong, et al.
Publicado: (2014)

1536. Donor-Derived Mycobacterium tuberculosis Infection After Solid-Organ Transplantation: A Comprehensive Review
por: Abad, Cybele Lara, et al.
Publicado: (2018)

Letermovir for the prevention of cytomegalovirus infection and disease in transplant recipients: an evidence-based review
por: El Helou, Guy, et al.
Publicado: (2019)

Non-tuberculous mycobacterial infections in solid organ transplant recipients: An update
por: Abad, Cybele L., et al.
Publicado: (2016)

Stewardship of COVID-19 volunteers by nested trial design
por: Gottlieb, Robert L, et al.
Publicado: (2022)

Coronavirus Disease 2019 Management Strategies in Solid Organ Transplant Recipients
por: Mendoza, Maria Alejandra, et al.
Publicado: (2023)

Effectiveness of Monoclonal Antibodies in Preventing Severe COVID-19 With Emergence of the Delta Variant
por: O’Horo, John C., et al.
Publicado: (2022)

Reply: Antifungal Prophylaxis
por: Pennington, Kelly M., et al.
Publicado: (2021)

1552. Absolute Lymphocyte Threshold: A Simple Readily Available Tool to Predict Risk of Cytomegalovirus Infection After Transplantation
por: Meesing, Atibordee, et al.
Publicado: (2018)

445 Epidemiology and Outcomes of Clostridium difficile Infections in Heart and Heart-lung Transplant Recipients
por: Bruminhent, Jackrapong, et al.
Publicado: (2014)

Cryptococcus Species Other Than Cryptococcus neoformans and Cryptococcus gattii: Are They Clinically Significant?
por: Cano, Edison J, et al.
Publicado: (2020)

454 Cytomegalovirus (CMV) Disease after Lung Transplantation (LT) is associated with increased mortality despite Extended Antiviral Prophylaxis
por: Beam, Elena, et al.
Publicado: (2014)

322. Joint Spacer Retention, Antimicrobial Suppression, and Risk of Re-infection
por: Valencia, Jose Carlo, et al.
Publicado: (2018)

1691. Cryptococcus Species Other than C. neoformans and C. gattii: Are They Clinically Significant?
por: Cano Cevallos, Edison J, et al.
Publicado: (2019)

Long-term Outcomes of Patients With Human Herpesvirus 6 Encephalitis
por: Fida, Madiha, et al.
Publicado: (2019)

Rates of Severe Outcomes After Bamlanivimab-Etesevimab and Casirivimab-Imdevimab Treatment of High-Risk Patients With Mild to Moderate Coronavirus Disease 2019
por: O’Horo, John, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_it7hk3je49k1kf6u5dg7sastcj